nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1

Home nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1

nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1

nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1

/ Publications

Share the Post

About the Author

Related Posts

A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
Read More
Anupam Dalal, MD
Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1 and TSC2 Inactivating Alterations
Read More
Emma Reeve
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Comments

Comments are closed.